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Sorsby fundus dystrophyTissue inhibitors of metalloproteinases (TIMPs) are widely distributed in the animal kingdom and the human
genome contains four paralogous genes encoding TIMPs 1 to 4. TIMPs were originally characterized as
inhibitors of matrix metalloproteinases (MMPs), but their range of activities has now been found to be
broader as it includes the inhibition of several of the disintegrin-metalloproteinases, ADAMs and ADAMTSs.
TIMPs are therefore key regulators of the metalloproteinases that degrade the extracellular matrix and shed
cell surface molecules. Structural studies of TIMP–MMP complexes have elucidated the inhibition
mechanism of TIMPs and the multiple sites through which they interact with target enzymes, allowing
the generation of TIMP variants that selectively inhibit different groups of metalloproteinases. Engineering
such variants is complicated by the fact that TIMPs can undergo changes in molecular dynamics induced by
their interactions with proteases. TIMPs also have biological activities that are independent of
metalloproteinases; these include effects on cell growth and differentiation, cell migration, anti-
angiogenesis, anti- and pro-apoptosis, and synaptic plasticity. Receptors responsible for some of these
activities have been identiﬁed and their signaling pathways have been investigated. A series of studies using
mice with speciﬁc TIMP gene deletions has illuminated the importance of these molecules in biology and
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The appropriate assembly of the extracellular matrix (ECM) from its
many components is essential inmulticellular organisms for organizing
cells and tissues and maintaining a suitable environment for cellular
functions. Changes in ECM composition are crucial for embryonic
development, morphogenesis, tissue remodeling and repair. The major
proteinases involved in ECM catabolism are the matrix metalloprotei-
nases (MMPs), which include collagenases, gelatinases, stromelysins,
matrilysins, membrane-type MMPs and others [1] and the ADAMTS (a
disintegrin and metalloproteinase with thrombospondin domains)metalloproteinases [2]. Themembrane-anchored ADAMmetalloprotei-
nases, often called “sheddases”, also affect cellular behavior by
proteolytically releasing the extracellular domains of cell surface
molecules such as membrane-bound growth factors, cytokines and
cell adhesion molecules [3]. The activities of these metalloproteinases
are precisely regulated under physiological conditions at the levels of
transcription, zymogen activation and inhibition by endogenous
inhibitors. Disruption of the balance between the production of active
enzymes and their inhibition may result in diseases associated with
uncontrolled ECM turnover, inﬂammation, cell growth and migration,
such as arthritis, cardiovascular disease, cancer, pulmonary disease,
nephritis, neurological disorders and tissue ulceration. Tissue inhibitors
of metalloproteinases (TIMPs) are endogenous inhibitors of these
metalloproteinases and are consequently important regulators of ECM
turnover, tissue remodeling and cellular behavior.
The inhibitory activity of TIMP-1was discovered in the early 1970s
in the form of a collagenase inhibitor in the media of cultured human
skin ﬁbroblasts [4], human serum [5], and in extracts of bovine
cartilage and aorta [6]. The inhibitorwas puriﬁed and found to be a 25–
31 kDa protein in 1979 [7,8]. It was later designated “tissue inhibitor of
metalloproteinases” or “TIMP” as it inhibited not only collagenases, but
also gelatinases and proteoglycanase (now called matrix metallopro-
teinase 3/MMP-3) [9]. The human genome has 4 paralogous genes
encoding TIMPs (TIMPs-1 to -4). All four TIMPs inhibitMMPs, but with
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four TIMPs, TIMP-3 has the broadest inhibition spectrum as it inhibits
severalmembers of the ADAMandADAMTS families [10]. It also differs
from the others in being tightly bound to the extracellular matrix [11].
In addition to their metalloproteinase inhibitory activity, TIMPs have
various biological activities such as promoting cell proliferation, anti-
angiogenic, pro- and anti-apoptotic and synaptic plasticity activities,
many of which are independent of metalloprotease inhibition.
In 2000, we reviewed the structure, function and evolution of
TIMPs [12]. Since then considerable progress has been made in the
ﬁeld; genome projects have shown that the TIMP family is widely
distributed in the animal kingdom and is structurally diverse.
Structural studies have led investigators to generate TIMP mutants
with selective inhibitory activities and we have begun to understand
the molecular mechanisms through which TIMPs elicit metallopro-
teinase-independent biological activities. This review focuses on these
topics by interlacing earlier “classical” work and recent advances.
2. Genes and protein structures of TIMPs
The four TIMPs encoded by the human genome are the most
extensively characterized with respect to structure, activity and
biological function. Although a comprehensive survey has not been
made, it appears that orthologues of all four human TIMPs are present
in other mammals. Homologues of the TIMPs are distributed widely
among both invertebrate and vertebrate animals, but there is limited
information available on the properties of non-mammalian TIMPs.
Structural similarities between TIMPs and other proteins have also
been noted, e.g. netrins, agrins and some bacterial proteins [13].
Before discussing the larger protein family, we review the structures
and properties of the well-characterized mammalian TIMPs.
2.1. Mammalian TIMPs
Some of their general properties are summarized in Table 1. The
genes for TIMPs-1, -3 and -4, but not TIMP-2, are each nested within an
intron in the genes for synapsins; TIMP-1 is associated with synapsin 1,
TIMP-3 with synapsin 3 and TIMP-4 with synapsin 2. Synapsins are
peripheral neuronal proteins that coat the cytoplasmic surfaces of
synaptic vesicles. This inter-relationship appears to be ancient because
the gene for the single TIMP inDrosophila melanogaster is nested withinTable 1
A summary of the general properties of the four human TIMPs.
Property TIMP-1 TIMP-2
Glycosylation Yes No
pI 8.47 6.48
No. of residuesa 184 194
Mr
b 20,709 21,755
MMP inhibition Weak for MMP-14 -16, -19, and -24 All
Other MP inhibition ADAM10 ADAM12
Pro-MMP interactions Pro-MMP-9 Pro-MMP
Other partners CD63 and LRP-1 (MMP-9 complex) α3β1 inte
LRP-1
Apoptotic effects Negative Positive
Negative
Angiogenesis Negative Negative
Chromosomal location: human X11p11.23–11.4 17q23–25
Mouse X A1.3 11 E2
Synapsin genec I None
Genetic disorder
aMature protein.
bExcluding any glycans.
cNested in intron V of the listed synapsin.
dInhibited by N-terminal domain of TIMP-4.an intron of the onlyDrosophila synapsin (Syn) gene [14]. In the genome
of Fugu rubripes, the tiger blowﬁsh, a pair of nested Syn–Timp genes, are
present together with a Syn gene that does not contain a Timp, but there
are two Timp genes that are separate from Syn genes [15]. The nested
gene arrangement suggests the possibility of coordinated transcription
or alternative splicing between TIMP and synapsin genes, but there
appears to be no evidence that this occurs. The gene for TIMP-2 is not
nested within a Syn gene, but hosts the gene DDC8 (differential display
clone 8), a gene that is expressed in the testis at an enhanced level
during spermatogenesis. Recent studies indicate that this gene is also
expressed in other tissues in a manner similar to TIMP-2, e.g., in
response to an injury to the cerebral cortex. A regulatory relationship
between the two genes is suggested by an alternative spliced mRNA
variant involving the two genes [16].
All mammalian TIMPs have two distinct domains, an N-terminal
domain of about 125 amino acid residues and a C-terminal domainwith
about 65 residues; the conformation of each domain is stabilized by
three disulﬁde bonds [17]. The four human TIMPs are about 40%
identical in sequence to each other; the most similar pair is TIMP-2 and
TIMP-4, which are 50% identical in sequence, whereas TIMP-1 is only 37
to 41% identical to the other TIMPs. Although the N- and C-terminal
regions of TIMPs have been described as “subdomains” [18], the more
deﬁnitive term “domain” is appropriate because of their separate
evolutionary origin and ability of the N-terminal region to fold and
function independently. Recombinant forms of the N-terminal domains
of TIMPs, designated N-TIMPs, expressed in heterologous systems, have
stable native structures and are fully active as inhibitors of matrix
metalloproteinases (MMPs) and some disintegrin-metalloproteinases
(ADAMs and ADAMTSs) [19–22]. N-TIMPs have been widely used in
characterizing the biochemical and biophysical properties of TIMPs and
for investigating structure–function relationships.2.2. Functional specialization for metalloproteinase inhibition
The four human TIMPs are, in general terms, broad-spectrum
inhibitors of the 23 MMPs found in humans, but there are some
differences in speciﬁcity among them. TIMP-1 is more restricted in its
inhibitory range than the other three TIMPs, having a relatively low
afﬁnity for the membrane-type MMPs, MMP-14, MMP-16, and MMP-
24 as well as for MMP-19 [10]. Also, there are some relatively subtle
differences between the afﬁnities of different TIMPs for other MMPs.TIMP-3 TIMP-4
Partial No
9.14 7.21
188 194
21,690 22,329
All Most
ADAM10, 12, 17, 28 and 33; ADAMTS-1, -4, and -5
ADAMTS-2 (weak)
ADAM17d and 28
ADAM33 (weak)
-2 Pro-MMP-9 and pro-MMP-2 Pro-MMP-2
grin EFEMP1, VEGFR2 and Angiotensin II receptor
Positive
Negative Negative
22q12.1–q13.2 3p25
10C1–D1 6 E3
III II
Sorsby fundus dystrophy
Table 2
PDB codes of crystal structures of TIMP-metalloproteinase complexes and the
involvement of interaction regions, IRs III–V. See the text and Fig. 2 for deﬁnition of IRs.
Complex Pdb code Buried surface (Å2) IR III IR IV IR V
Inhibitory
TIMP-1–MMP-3 1UEA 2000 + +/− −
N-TIMP-1–MMP-3 1UEA 1400 (calculated) + +/− −
TIMP-2–MMP-14 1BUV 2500 + + −
TIMP-2–MMP-13 2E2D 2440 + + −
N-TIMP-1–MMP-1 2JOT 1500 − +/− −
N-TIMP-3–ADAM17 3CKI 2120 + + +
Non–inhibitory
TIMP-2–pro-MMP-2 1GXD 2489 − − −
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MMP-3 and MMP-7, contrasting with their afﬁnities for other MMPs
[23]. TIMP-3 is unique among the mammalian TIMPs in inhibiting a
broader array of metalloproteinases including several members of the
ADAM and ADAMTS families [21,22,24–27]. Other TIMPs have limited
inhibitory activities for ADAMs: TIMP-1 and TIMP-2 inhibit ADAM10
[24] and ADAM12 [27] respectively. N-TIMP-3 and N-TIMP-4, but not
full-length TIMP-4, inhibit ADAM17 [28]. TIMP-4 was also reported to
inhibit ADAM28 [29]. ADAMmetalloproteinases differ from theMMPs
in domain structures and are highly divergent in catalytic domain
sequences: ADAMs are membrane-bound enzymes containing disin-
tegrin, cysteine-rich, EGF-like and transmembrane domains C-
terminal to their catalytic domains [3]; and ADAMTS (disintegrin-
metalloproteinases with thrombospondin motifs) are secreted pro-
teins with a disintegrin domain and variable numbers of thrombos-
pondin type 1 motifs and other domains in their C-terminal regions
[2]. In humans there are 21 members of the ADAM family, of which
only 13 are functional proteases, and there are 19 ADAMTSs.
The ﬁrst non-MMP metalloproteinase reported to be inhibited by
TIMP-3 was ADAM17, also known as tumor necrosis factor-α
converting enzyme or TACE [21]. ADAM17 catalyzes the release of
soluble tumor necrosis factor α (TNF-α) from its membrane-bound
precursor as well as the shedding of transforming growth factor
(TGF)-α, various receptors, L-selectin and Notch and the non-
pathogenic processing of amyloid precursor protein as an α-secretase
[30]. It has now been established that TIMP-3 is an effective inhibitor
of ADAM10, 12, 17, 28 and 33, and ADAMTS-1, -2, -4 and -5 [10].
ADAMTS-4 and -5 are also called aggrecanases 1 and 2, respectively.
The inhibition of ADAM17 and aggrecanases by TIMP-3 appears to be
important in regulating inﬂammatory processes, affecting the pro-
gression of disease processes such as cancer, rheumatoid arthritis and
osteoarthritis [31,32]. The interaction between TIMP-3 and ADAMTS-
4 is enhanced about 4-fold by aggrecan [33]. N-TIMP-3 is a weak
inhibitor of ADAMTS-2, procollagen N-proteinase, with a Ki of about
600 nM, but the inhibition is also enhanced by heparin to a Ki of
160 nM [26]. As a potentiator of TIMP-3 inhibitory action, the anti-
arthritic agent, calcium pentosan polysulfate, is remarkable; it
enhances the binding afﬁnity between TIMP-3 and ADAMTS-4 or -5
more than 100-fold and also blocks the endocytosis of TIMP-3 by
chondrocytes [34]. These results suggest that the anti-arthritic activity
of pentosan polysulfate is dependent on the endogenous TIMP-3 of
cartilage.
MMPs and ADAMs are usually inhibited by the N-terminal
domains of TIMPs, but Rapti et al. [35] found that while TIMP-1 and
TIMP-3 both inhibit ADAM10, their isolated N-terminal domains do
not. This indicates that the mechanism of inhibition of this enzyme by
TIMPs differs from those of MMPs and other ADAMs and ADAMTSs.
Full-length TIMP-3 and N-TIMP-3 are therefore useful agents for
discriminating between the activities of ADAM10 and ADAM17which
often share similar substrates.
2.3. Three-dimensional structures of TIMPs and their complexes
The structures of full-length TIMP-1 and TIMP-2, N-TIMP-1 and N-
TIMP-3 have been determined by X-ray crystallography [18,36–41] and
the solution structures of N-TIMP-1 andN-TIMP-2 have been elucidated
byNMR [42–44]. Most of the structures are of the bound forms of TIMPs
in their inhibitory complexes with their target metalloproteinases,
exceptions being the crystallographic structure of free TIMP-2 [37],
solution structures of free forms of N-TIMP-1 [45] and N-TIMP-2 [42],
and the structure of TIMP-2 in its complex with pro-MMP-2 which is
stabilized by interactions between the C-terminal domain of the
inhibitor and the hemopexin domain of the proenzyme [38] (Table 2).
The structures of full-length TIMP and N-TIMP have a “wedge-
shaped” appearance [18,42]. The N-domain has an oligonucleotide
and oligosaccharide binding (OB) fold [46], a ﬁve-stranded (β strandssA through sF) closed twisted β-barrel with a Greek key topology. This
domain also contains three α-helices, one located close to the N-
terminus (hI) and two (hII and hIII) near the C-terminus where they
form part of the interface with the smaller C-domain. The C-domain
has a pair of parallel β strands (sG and sH) connected by a loop,
followed by a helix (hIV) and a pair of antiparallel β-strands (sI and sJ)
connected by a β-hairpin (Fig. 1A).
The structure of the immediate N-terminal region is highly
conserved in all TIMPs, reﬂecting its crucial function in inhibiting
MMPs. The cysteines in the Cys1-X-Cys3 sequence are attached by
disulﬁde bonds to two other conserved cysteines, Cys70 and Cys100,
respectively (numbering based on the sequence of TIMP-1) (Fig. 1B).
The third Cys, residue 13, is disulﬁde bonded with Cys123, a residue that
delineates the C-terminus of the inhibitory domain. All structurally
characterized inhibitory TIMP-metalloproteinase complexes, including
the complex of N-TIMP-3withADAM17, are closely similarwith respect
to the core of the protein–protein interaction interface. The majority
(60–75%) of the interactions between a TIMP and a metalloproteinase
are made by the continuous ridge formed by the N-terminal ﬁve
residues, Cys1-Thr-Cys-Val-Pro5 in TIMP-1 (designated here IR I
(interaction region I)) and the loop connecting sC and sD (CD loop),
residues Met66-Glu-Ser-Val-Cys70 in TIMP-1 (IR II), that are covalently
fastened by the disulﬁde bond between Cys1 and Cys70 (see Fig. 1). This
ridge inserts into themetalloproteinase active site in suchaway that the
conserved N-terminal Cys1 of the TIMP lies above the catalytic Zn2+ of
the MMP. A key to the mechanism of inhibition is the bidentate
coordination of the metal ion by the N-terminal α-amino group and
carbonyl group of Cys1, which displaces from the enzyme the water
molecule needed for peptide bondhydrolysis. Residue 2, which is Thr or
Ser in all TIMPs from vertebrates, interacts with the so-called S1′
speciﬁcity pocket of the MMP, a subsite that has a dominant role in
determining enzyme speciﬁcity. Residues 3–5 interact with primed
subsites (that interact with residues of the peptide substrate located to
the C-terminal side of the scissile bond) in the protease active site, while
Ser68 and Val69 interact with non-primed subsites S2 and S3 (that
interactwith residues of the peptide substrate located to the N-terminal
side of the scissile bond) of the MMP (Fig. 1B).
Other regions that contribute to the interaction site are the AB loop
(IR III) that lies to the right of the CD loop, and the EF loop (IR IV)
(Fig. 1A). There is a large variation in the size of the AB loop among
different TIMPs and this inﬂuences their interactions withMMPs. In the
complex of N-TIMP-3 with the catalytic domain of ADAM17, there are
also signiﬁcant interactions involving the C-terminal end of sD (IR V)
that are not observed in other structurally characterized TIMP
complexes [41]. It is not clear whether these occur in complexes of
TIMP-3 with MMPs or are unique to the interaction with ADAM17 and
possibly other ADAMs.
In the complexes formed between full-length TIMPs and the
catalytic domains of MMPs [18,36,40], there are some contacts
between the C-domain of the TIMP and the protease, but these are
on the periphery of the interaction site and do not appear to make
important contributions to complex formation because the truncated
Fig. 1. Structure of TIMP-1 and its metalloproteinase interaction regions. (A) A ribbon structure of the three-dimensional structure of TIMP-1 showing the locations of the disulﬁde
bonds, the two domains, domain interface and regions (IR I to V) that interact with metzincins and their component residues. This image was generated using Chimera [177]. (B) The
structure of the core of the TIMP interaction site indicating interactions with individual subsites in MMP active sites.
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binding kinetics of TIMP-2 with full-length MMP-2 suggest a much
higher afﬁnity (6 fM) [47] compared with MMP-2 that lacks the
hemopexin domain (275 nM) [48]. This afﬁnity of N-TIMP-2 for full-
length MMP-2 was less, although remaining high (40 pM), suggesting
that the C-terminal domain of TIMP-2 makes some stabilizing
interactions with the C-terminal hemopexin domain of MMP-2.
Complexes of TIMP-1 or TIMP-3 with ADAM10 are also expected to
have substantial contacts through the C-domain as N-TIMPs fail to
inhibit ADAM10 [35]. In contrast, the C-terminal non-catalytic
domains in ADAM17 have unfavorable effects on the interaction
with N-TIMP-3 [49]. The interaction of TIMP-3 with ADAM17 also
differs from those with MMPs in showing cooperative binding, which
suggests the presence of multiple TIMP-3 binding sites, and also in the
mode of interaction since an N-terminal Ala extension in N-TIMP-3
has a relatively small effect on the inhibition [50].
While close contacts between IR I and IR II and the metallopro-
teinase are found in all known TIMP complexes, the other regionshave variable roles depending on the TIMP and on the target enzyme.
Further detailed structural studies are required since such information
will be useful for engineering TIMPswith restricted inhibitory spectra.
2.4. Interactions with pro-MMPs
The complexes of TIMPs with pro-MMPs are stabilized by
interactions of the C-terminal domains of TIMP with the hemopexin
domains of the zymogen. The interactions of TIMPs with pro-MMPs
are relatively speciﬁc: TIMP-2, TIMP-3 or TIMP-4 with pro-MMP-2
and TIMP-1 or TIMP-3 with MMP-9 [10]. Since the interactions in
these complexes do not involve the N-terminal domain of the TIMP,
the complexes are capable of interacting with a second MMP
molecule. However, with the exception of the pro-MMP-2-TIMP-2
complex, their functional signiﬁcance is unclear.
The interaction of TIMP-2 with pro-MMP-2 is part of the activation
mechanism of pro-MMP-2. In this process, membrane-type-1 MMP
(MT1-MMP orMMP-14) plays a key role. The catalytic domain ofMMP-
Fig. 2. A phylogenetic tree showing the inferred evolutionary relationships between
vertebrate TIMPs-1, -2, -3, and -4, rooted by the single TIMP from Drosophila
melanogaster. This was generated using Phylogeny.fr (www.phylogeny.fr) in “One
Click” mode [178].
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terminal domain of TIMP-2 and forms a cell membrane-associated
ternary complex. No component of this complex is proteolytically active
but the activation of the pro-MMP-2 component is triggered by cleavage
of its pro-domain by a second MMP-14 molecule. This is facilitated by
interactions between the two MMP-14 molecules through their
hemopexin domains [51]. The activation is completed by autolytic
cleavage by MMP-2 [52]. The crystallographic structure of the complex
of TIMP-2with pro-MMP-2 shows they have two interaction interfaces.
One is the loop between β-strands G and H of TIMP-2 and the 4th blade
of the 4-bladed β-propeller structure of the hemopexin domain of pro-
MMP-2, and the second involves the C-terminal tail region of TIMP-2
that follows the last cysteine in the sequence; this is inserted between
the 3rd and 4th propeller blades [38]. TIMP-4 can also interact with pro-
MMP-2 andeven forma ternaryMMP-14-TIMP-4-pro-MMP-2 complex,
but this does not lead to the activation of pro-MMP-2 [53,54]. In fact,
TIMP-4 is an effective inhibitor of pro-MMP-2 activation through its
inhibitory action on MMP-14 [54]. A similar terminal complex that
cannot be activated is formed with TIMP-3. TIMP-3 is therefore
inhibitory for pro-MMP-2 activation. TIMP-3−/− cells display enhanced
activation of pro-MMP-2 by MMP-14 [55]. Domain swapping muta-
genesis studies with TIMP-2 and TIMP-4 show that the C-domain of
TIMP-2 is the key to pro-MMP-2 activation since a N-TIMP-4/C-TIMP-2
hybrid can support activation, and further deletion of the C-terminal tail
of TIMP-2 (residues 186–194) leads to a loss of its ability to promote
pro-MMP-2 activation, indicating the functional importance of this tail
region [56].
3. Non-mammalian TIMPs
3.1. Vertebrates
Although four human TIMPs appear to be present in all
mammalian species, their orthologues are not present in all
vertebrates (Fig. 2). For example, there appears to be no orthologue
of TIMP-1 in chickens, and the zebraﬁsh (Danio rera) has four TIMPs,
all of which are most similar in sequence to human TIMP-2 [57]. On
the other hand, a search of EST databases suggests that cartilaginous
ﬁshes have an orthologue of mammalian TIMP-3 but no other TIMPs,
whereas bony ﬁshes have orthologues of both TIMP-2 and TIMP-3.
However, in more distantly related species the relationships of TIMPs
with speciﬁc mammalian TIMPs are less clear.
3.2. Invertebrates
TIMPs from invertebrates are more variable in sequence than
those from vertebrates. Apart from the homologues from nematodes,
all are two-domain proteins that, with a few exceptions, have
arrangements of cysteines that are similar to those of their
mammalian relatives (see Fig. 3). However, a large proportion of
invertebrate TIMPs have eight cysteines rather than six in their C-
terminal domains. Some species, for example, D. melanogaster, have a
single TIMP, whereas others have multiple TIMPs (e.g. hydra).
Regions of the alignment show striking variations in length. For
example, some species variants have large insertions between the
third and fourth cysteines of the N-terminal domain (Fig. 3), that
appear to reﬂect variations in length of the AB loop and in the loop
between β strands B and C. A single 2-domain TIMP molecule in
insects has been suggested to reﬂect the origin of the four
mammalian TIMPs from a single common ancestor during vertebrate
evolution. The four TIMPs found in the purple sea urchin and the
three TIMPs in Hydra magnipapillata do not correspond to the
mammalian subtypes. Nematodes have genes for multiple TIMP
homologues that are generally single-domain proteins corresponding
to the N-terminal inhibitory domains of mammalian TIMPs but have
no region corresponding to the C-domains of mammalian TIMPs [12].Although this suggests that the single-domain protein is a model for
the ancestral protein, H. magnipapillata, which is thought to have
diverged from the line leading to the vertebrates at a more ancient
time than ﬂies and nematodes [58], has a two-domain TIMP.
Therefore, the single-domain nematode TIMP may have developed
by loss of a domain from a two-domain ancestor or it could represent
a distinct gene line. Based on this consideration and the variable
numbers of subtypes in different species, TIMP evolution does not
appear to have been a linear process in the invertebrates.
The TIMP homologues from nematodes have the characteristic
pattern of cysteines and other conserved regions of sequence that are
found in the N-domain of TIMPs and some netrin-fold proteins. They
also have a secretion signal sequence. However, the amino acid
residue present at position 2 in the mature forms of some of these
proteins are atypical for a TIMP, for example, Lys, Arg or Gln.
Substitution of these amino acids for Thr 2 in human TIMP-1 is known
to produce a major loss of afﬁnity for MMPs [59]. This suggests the
possibility that these proteins, although homologouswith the TIMPN-
domains, may not function as MMP inhibitors. Recently, a TIMP
homologue from the hookworm, Acylostoma caninum, was cloned and
expressed as a His-tagged form cytoplasmically in E. coli [60]. It was
soluble and, after puriﬁcation, was found to have inhibitory activity
against some human MMPs. The inhibition studies were conducted at
a single relatively high inhibitor concentration of about 500 nM [60].
The implications of these results are unclear, because disulﬁde bonds
do not readily form in proteins expressed in the cytoplasm of E. coli
(other TIMPs have been found to be expressed in E. coli as denatured
inclusion bodies and require oxidative in vitro folding to become
active), and also because such a high concentration was required for
MMP inhibition. One possible interpretation is that the TIMP
Fig. 3. An alignment of the complete amino acid sequences of TIMPs from invertebrates. The location of secondary structure elements projected from the known three-dimensional structures of mammalian TIMPs are marked underneath. “E”
denotes residues in extended structures (β-strands) while bars identify α-helices. The species from which the TIMPs are derived are abbreviated as follows: Hydra, Hydra magnipapillata; Nematostella, Nematostella vectensis (sea anemone);
Mytilus, Mytilus californianus (mussel); Strong, Strongylocentrus purpuratus (sea urchin); Crassostrea, Crassostrea gigas (oyster); HumanT3, human TIMP-3; Branchiostoma, Branchiostoma ﬂoridae (Florida lancelet); Drosophilam, Drosophila
melanogaster; Tribolium, Tribolium castaneum (red ﬂour beetle); Culex, Culex quinquefasciatus (Southern house mosquito); Aedes, Aedes aegypti (yellow fever mosquito); Clytia, Clytia hemisphaerica (jellyﬁsh).
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substrate.
3.3. Characterization of invertebrate TIMPs
There have been some studies of expression patterns of TIMPs in
non-mammalian species including invertebrates [61–63], but only
limited information is available regarding the functional properties of
invertebrate TIMPs. Wei et al. cloned the N-terminal inhibitory
domain of the single TIMP from a D. melanogaster embryonic cell
library (dN-TIMP) and expressed it in E. coli as inclusion bodies. The
protein was folded and puriﬁed and found to be an effective inhibitor
of the two MMPs from Drosophila in vitro [64]. These studies were
only semi-quantitative because of the relatively low activities of
Drosophila MMPs on synthetic substrates, but more rigorous studies
with mammalian MMPs showed that dN-TIMP inhibits MMPs-1, -2,
and -14. It resembles human N-TIMP-3 in being a potent inhibitor of
ADAM17, but it is a relatively weak inhibitor of ADAM10; this is not
surprising because of the weak inhibitory activity of human N-TIMP-1
and N-TIMP-3 for ADAM10 [35]. The relatively low activity against
mammalian MMP-1, a collagenase, was proposed to reﬂect an
adaptation to differences in the composition of the extracellular
matrix between insects and vertebrates. The Drosophila genome
contains no genes for ﬁbrillar collagens. Thus, Drosophila TIMP
(dTIMP) would not be under selective pressure to acquire or maintain
features required to bind effectively to the active sites of collagenases
that cleave ﬁbrillar collagens. Based on modeling, dN-TIMP appears
similar in surface charge properties to N-TIMP-3. It is also closer to
mammalian TIMP-3 in sequence, functional properties and predicted
structure than to the other three TIMPs [64]. Disruption of Timp in
Drosophila generates a subviable phenotype. In adult ﬂies, this
mutation produces inﬂated wings, bloated guts and tissue autolysis,
impaired phototactic responses, and premature death, indicating that
active dTIMP is needed for balanced ECM turnover, appropriate cell–Fig. 4. A comparison of some bacterial homologues with the N-domains of human TIMP-2 an
Acaryochloris, hypothetic protein AM1_44443 from Acaryochloris marina MBIC11017; Bacillu
from Bacillus cereus G9241; Bacillus_thur, hypothetical protein BT9727_1673 from Bacillus th
Bacillus cereus G9241; Geobacillus, hypothetical protein GYMC10DRAFT_3737 from Geobac
paciﬁca SIR-1. Other abbreviations are HumanT2, human N-TIMP-2; HumanT3, human N-TIcell or cell–matrix interactions and a functional nervous system in
Drosophila [65].
In contrast to the situation in insects, ﬁbrillar collagens have awide
distribution in many other invertebrate species, being present in
cnidarians such as hydra and sea anemone as well as the choano-
ﬂagellate, Monosiga brevicollis and the demosponge, Amphimedon
queenslandica. The most recent common ancestor of cnidarians is
thought to be more ancient than that of insects [57], so that it appears
that ﬁbrillar collagen genes may have been lost in the line leading to
insects. Most or all metazoans appear to have genes that encode
TIMPs that might be expected to function as metalloproteinase
inhibitors. While there is little information about their functional
properties, it is reasonable to speculate that they also regulate
turnover of ECM components including ﬁbrillar collagens.3.4. Bacteria
Structural studies show similarities between TIMPs and other OB-
fold proteins from vertebrates that have distinct functions. The latter
includes netrins which have a N-TIMP-like netrin (NTR) domain, the
laminin-binding domain of agrin, the C-terminal C345C domain of
complement proteins C3, C4 and C5, and a domain of type I
procollagen C-proteinase enhancer [13,66]. These domains have
similar 3D structures to the N-domains of TIMPs but their sequences
do not align readily with those of the TIMPs. In contrast, several
bacterial proteins show signiﬁcant similarities in sequence to TIMPs,
particularly to TIMP-2; their amino acid sequences ﬁsh out vertebrate
TIMP sequences in BLAST searches and vice versa. The sequences of
these proteins all start with a bacterial secretion signal sequence; an
alignment of the predicted sequences of the mature forms of the
proteins with N-TIMP-2 is shown in Fig. 4. Some of these proteins are
designated as having a cbiN-domain, but their functions appear to be
unknown at present.d -3 and Drosophila melanogaster TIMP. The sequences are from the following sources:
s_cerQ1, cbiN-domain protein from Bacillus cereus Q1; Bacillus_cer, hypothetical protein
uringiensis serovar konkukian str. 97-27; Bacillus_cereus9241, hypothetical protein from
illus sp. Y412MC10; Plesiocystis, hypothetical protein PPSIR1 _33491 from Plesiocystis
MP-3; DmT, N-terminal domain of D. melanogaster TIMP.
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The uncontrolled activities of MMPs, ADAMs and ADAMTSs have
been linked to multifarious diseases in humans including cancer,
rheumatoid arthritis, osteoarthritis, encephalomyelitis, heart, lung and
kidney diseases. Thus, they are attractive targets for the development of
speciﬁc inhibitors with potential clinical applications. At the same time,
these metalloproteinases share generally similar active site structures
and have overlapping speciﬁcities and numerous key roles in important
biological processes. This may have contributed to the lack of success in
clinical trials of synthetic MMP inhibitors [67]. An alternative approach
to the therapy of metalloproteinase-related diseases could be to use
engineered TIMPs with restricted inhibitory speciﬁcities. Natural TIMPs
are broad-spectrum inhibitors, particularly for MMPs, but they have
relatively large interaction interfaces and differ in the types of
interactions that they make with different metalloproteinases as seen
in the crystallographic structures of TIMP-1 and TIMP-2 with different
MMPs [37,39–41]. This suggests that their afﬁnities for different MMPs
can be manipulated by mutagenesis. Most mutagenesis studies have
used N-TIMPs as they are readily expressed in bacterial systems and
folded from the inclusion bodies.
Earlier mutational studies of N-TIMP-1 focused on Thr2 as a
residue that inﬂuences the afﬁnity for different MMPs [59]. This was
based on the fact that residue 2 of TIMP-1 interacts with the S1′
subsite of MMPs, the speciﬁcity pocket that has a key role in substrate
speciﬁcity [68,69]. Analysis of the effects of ﬁfteen different substitu-
tions for Thr2 on the inhibition of MMPs-1, -2 and -3 indicated that
side chain size, charge and hydrophobicity are properties that make
key contributions to MMP selectivity. However, the effects of these
substitutions on MMP selectivity showed little correlation with the
effects of the same amino acid in the P1′ position of a peptide
substrate, indicating that structural constrains of TIMP around the
reactive site is different from ﬂexible peptide substrates. The
importance of residue 2 in MMP inhibition was also indicated by
the fact that the removal of the side chain (a mutation to glycine)
resulted in a loss of 33–55% of the free energy of complex formation
while other substitutions differentially affected binding to the three
MMPs. This suggested that residue 2 of this TIMP can be considered to
be a “hot spot” in the TIMP–MMP interaction interface [59]. More
recent studies, however, have shown that the Thr 2 to Gly substitution
has a relatively small effect on the afﬁnity of N-TIMP-1 for MMP-9,
suggesting that interactions outside of the S1′ pocket are more
important in the interaction with MMP-9 than with other MMPs [23].
Other mutational studies have shown that substitutions for other
residues in the TIMP reactive site also affect speciﬁcity, although less
dramatically those involving residue 2. These studies have been
extensively reviewed by Nagase and Murphy [10] and will not be
discussed in great detail here. In brief, it can be said that residues 4, 68
and 98 (TIMP-1 numbering) have relatively large effects on inhibitory
speciﬁcity.
The AB loop varies considerably in length between different TIMPs.
The shortest is in TIMP-1, and this is extended by 1 residue in TIMP-3,
by 6 residues in TIMP-4 and by 7 residues in TIMP-2. The long loop of
TIMP-2 makes extensive contacts with MT1-MMP (MMP-14) in their
inhibitory complex [36]; the shortest loop in TIMP-1might be thought
to provide an explanation of why TIMP-1 is a weak inhibitor of this
and some other MT-MMPs. However, grafting the longer AB loop from
TIMP-2 into the N-TIMP-1 structure does not enhance its binding to
MMP-14 [23]. Lee et al. [70] have reported that residue 98 (TIMP-1)
which is Thr in TIMP-1 and Leu in TIMP-2 is a key to the high afﬁnity
binding to MMP-14 and additional substitutions of Ala for Val4 and
Leu for Pro6 further enhanced binding. The N-TIMP-1(T98L) mutant
inhibits ADAM17 and MMP-19 as well as MT-MMPs [71]. Grafting the
AB loop from TIMP-3 into the N-TIMP-1(V4S/V69L) mutant greatly
improved the inhibitory action on ADAM17 [71]. In this case themutant
TIMP has better inhibitory afﬁnity for ADAM17 than N-TIMP-3. Otherstudies support the view that these residues, and others that have not
yet been identiﬁed, contribute to the weak binding of TIMP-1 to
membrane-type MMPs [23].
These studies represent the successful application of rational
structure-based engineering of TIMPs for developing variants with
selective inhibitory action on MMPs and other metalloproteinase
family members. However, protein–protein interactions are complex
phenomena involving dynamic molecules that undergo binding-
induced structural changes that can have varying effects on the
thermodynamics of binding. Structural and calorimetric studies of the
N-TIMP-1-MMP-3 interaction have illustrated this. Structural changes
that occur during this interaction include the displacement of the N-
terminal region of the MMP by disrupting a salt bridge [18], while
NMR studies indicate that structural adjustments occur in the TIMP
component throughout the enzyme reactive ridge formed by the two
regions linked by the Cys1–Cys70 disulﬁde [45]. Calorimetric studies
have shown that the N-TIMP-1-MMP-3 interaction is associated with
a positive (unfavorable) change in enthalpy and that, thermodynam-
ically, the interaction is driven by a strongly positive (favorable)
entropy change. Generally a positive entropy change in a protein–
protein interaction arises from increased solvent entropy due to the
release of ordered water molecules from non-polar regions of the
interaction interfaces; this would be reﬂected in a large negative
change in heat capacity (ΔCp) for the interaction. The small ΔCp for
the N-TIMP-1-MMP-3 interaction together with NMR studies suggests
that much of the entropy contribution to binding arises from
increased dynamics in the core of the TIMP β-barrel [72]. The
relatively high crystallographic B-factors observed in the N-TIMP-3
component of the N-TIMP-3–ADAM17 complex, as comparedwith the
ADAM17 component, suggests that this interaction might also
associated with an increase in conformational entropy in the TIMP
component [41]. Although B-factors are a measure of dynamics, they
can be affected by molecular contacts in a crystal as well as the
intrinsic mobility of components of the structure. The fact that the
entropy-driven binding, in at least one system, is independent of the
hydrophobic effect is somewhat problematic for structure-based
engineering.
5. TIMPs are multifunctional proteins
TIMPs have various biological activities including the modulation
of cell proliferation, cell migration and invasion, anti-angiogenesis,
anti- and pro-apoptosis and synaptic plasticity. These activities may
partially arise from metalloproteinase inhibition, as the regulation of
ECM catabolism can inﬂuence cellular behavior, but many of them
have been shown to be independent of MMP inhibition, because
synthetic MMP inhibitors or TIMP mutants that do not inhibit MMPs
can exhibit a similar activity. In the latter case, TIMPs interact directly
with speciﬁc cell surface receptors to induce cellular responses (see
Table 1 and a recent review by Stetler-Stevenson [73]).
5.1. Cell growth promotion
When the cDNA for TIMP-1was ﬁrst cloned [74], it was found to be
identical to a factor that has erythroid potentiating activity [75]. Later,
TIMP-1 was shown to have cell growth promoting activity on various
cell types including keratinocytes and ﬁbroblasts [76,77]. TIMP-2 also
has erythroid potentiating activity [78] and cell growth promoting
activity on many cell types [79] including metanephric mesenchyme
cells during nephron morphogenesis [80]. These effects are indepen-
dent of MMP inhibition, because TIMPs that lack MMP inhibitory
activity either by mutations or reduction and alkylation retained cell
growth promoting activity [81] and they were not produced by
synthetic MMP inhibitors. In an investigation of the cellular events
associated with TIMP-induced cell growth, Wang et al. [82] found that
both TIMP-1 and TIMP-2 increased the level of Ras-GTP, but utilize
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mitogen activated protein kinase (MAPK) pathway, whereas TIMP-2
signaling is mediated by protein kinase A activation which is di-
rectly involved in Ras/phosphoinositide 3-kinase (PI3-K) complex
formation. This suggests that TIMP-1 and TIMP-2 have distinct
receptors. Recent studies have shown that TIMP-1 binds to CD63
[83] and TIMP-2 to α3β1 integrin [84], but these interactions have
been found to inhibit apoptosis and arrest cell growth, respectively.
Thus, the mitogenic activities of the two TIMPs are not explained by
the involvement of these receptors, although there seem to be some
similarities in the activation of signaling molecules and anti-apoptotic
effects may be, in part, related to an effect on cell growth. Recently,
D'Alessio et al. [85] have suggested that the effect of TIMP-2 on cell
growth is mediated through its binding to MMP-14 on the cell surface
and subsequent extracellular regulated kinase (ERK)1/2 activation.
Since a TIMP-2 mutant with an extra alanine added to the N-terminus
(Ala+TIMP-2), which does not bind to the active site of MMP-14,
also activated ERK1/2, it was suggested that the interaction between
TIMP-2 and MMP-14 does not involve the active site of the enzyme
[85]. This is, however, inconsistent with the observation that a
hydroxamate MMP inhibitor that blocks TIMP-2 binding to the active
site of MMP-14 inhibited MMP-14-dependent ERK1/2 activation and
abrogated cell growth. Further studies are needed to clarify the
mechanism by which the TIMP-2–MMP-14 system promotes cell
proliferation.
5.2. Cell growth arrest and anti-apoptotic activity of TIMP-1 and TIMP-2
lead to cell differentiation
In addition to their mitogenic activities, TIMP-1 and TIMP-2
suppress the growth of some cells. In vitro studies with human breast
epithelial (MCF10A) cells showed that TIMP-1 reduces their growth
rate by inducing cell cycle arrest at G1 through the down-regulation of
cyclin D1 via the up-regulation of cyclin-dependent kinase inhibitor
p27KIP1 [86]. TIMP-1 also has anti-apoptotic effects on other cell types
[87–90]. While this effect of TIMP-1 on hepatic stellate cells was
reported to be due to the inhibition of MMPs [90], the effects on other
cells are not mediated by MMP inhibition [87–89]. Using the MCF10A
cell system, Jung et al. [83] found that the anti-apoptotic activity is
mediated through TIMP-1 binding to CD63, a member of the
tetraspanin family. CD63 interacts with the β1 subunit of integrins
and the TIMP-1–CD63–integrin β1 complex thus constitutively turns
on survival signals through the activation of focal adhesion kinase
(FAK), PI3-K and ERK pathways [89,91], similar to transformed cell
survival signaling. In a 3D matrigel matrix, MCF10A cells form
polarized acinar-like structures. The maintenance of these structures
requires apoptosis in centrally located cells [83]. The over-expression
of TIMP-1 in these cells disrupts the structures by inhibiting caspase-
mediated apoptosis and ﬁlls the luminal space in the glandular
epithelial structure by reducing cell polarization. This is one of the
features of ductal cancer development and over-expression of TIMP-1
and its anti-apoptotic effect may be associatedwith oncogenic cellular
transformation.
TIMP-1 levels in serum and TIMP-1 expression in cancerous tissues
are associated with poor clinical outcomes in many types of cancer
[92–95]. One possible explanation for this is that an elevated level of
mesenchymal TIMP-1 increases hepatocyte growth factor (HGF;
scatter factor) signaling by blocking a sheddase (possibly ADAM10)
of the HGF receptor, cMet, making the liver more susceptible to
metastasis [96]. The over-expression of TIMP-1 also elevates HGF
and HGF-activating proteases in the liver [96]. Another potential cause
is a combination of cell cycle arrest and anti-apoptotic activities of
TIMP-1, which leads to cellular transformation. Guedez et al. [87]
found that TIMP-1-positive Burkitt's lymphoma cell lines were
resistant to Fas-dependent and Fas-independent (cold-shock, serum
deprivation and γ-irradiation) apoptosis, but TIMP-1 negative cellswere not. TIMP-1 promotes germinal center B cell survival and differ-
entiation to plasma cells by up-regulating CD40, CD23 and IL-10, and
down-regulating CD77 [97]. It also promotes plasmacytic/plasma-
blastic differentiation in Burkitt lymphoma cells [98], as well as
hematopoietic cell differentiation [99].
TIMP-2 suppresses growth factor-stimulated cell proliferation at
low to sub-nanomolar concentrations, similar to the concentrations
that enhance cell growth [79,100]. This suppressive effect was
shown to be mediated by the activation of adenylate cyclase,
increased intracellular cAMP levels and the activation of SH2-
protein tyrosine phosphatase-1 (SHP-1) which dampens the
activity of growth factor receptors [100] and inhibits p42/44
MAPK activation [101]. Stetler-Stevenson et al. [84] identiﬁed
α3β1 integrin as the receptor of TIMP-2, and showed that vascular
endothelial cell growth factor (VEGF)-A-stimulated or ﬁbroblast
growth factor (FGF)-2-stimulated endothelial cell proliferation is
inhibited through the interaction of TIMP-2 with this integrin; this
results in the transfer of the β1 integrin-associated SHP-1 to the
VEGF or FGF receptor and its de-phosphorylation. In addition, TIMP-
2 induces G1 growth arrest in endothelial cells through the de novo
synthesis of p27KIP1, which results in the inhibition of cyclin-
dependent kinases 4 and 2 and subsequent hypophosphorylation of
retinoblastoma protein [102]. These observations may explain how
TIMP-2 arrests cell growth and inhibits angiogenesis.
TIMP-2 is expressed in post-mitotic neurons [103] and promotes
cell differentiation and neurite outgrowth [104], as the result of cell
cycle arrest through decreased expression of cyclins B and D and
increased production of cyclin-dependent kinase inhibitor p21Cip.
TIMP-2 expression is found only in α3 integrin-positive cells [105],
suggesting that TIMP-2-α3β1 integrin interactions participate in
neurogenesis by withdrawing progenitor cells from the cell cycle
and permitting their terminal neuronal differentiation.
While cell cycle arrest and the inhibition of apoptosis appear to be
closely related to cell differentiation, as in case of TIMP-1, it is not clear
whether the anti-apoptotic activity of TIMP-2 is essential for its
differentiation-promoting activity because of the limited availability
of information about the apoptotic activity of TIMP-2. Nonetheless,
the over-expression of TIMP-2 in B16F10 murine melanoma cells
rendered these cell more resistant to apoptosis [106] and in a mouse
model of atherosclerosis, the over-production of TIMP-2 reduced
plaque instability and inhibited the apoptosis of macrophages and
macrophage-derived foam cells [107]. Lim et al. [108], on the other
hand, reported that TIMP-2 causes the apoptosis of activated T cells
and that this is due to inhibition of the cleavage of Fas ligand. Clearly,
further investigation of the effects of TIMP-2 on apoptosis in other cell
systems would be of considerable interest.5.3. TIMP-3 and apoptosis
TIMP-3 induces apoptosis in a number of cancer cell lines [109–112]
and rat vascular smooth muscle cells [113]. Smith et al. [111] proposed
that the pro-apoptotic effects of TIMP-3 result from its inhibition of
TACE (ADAM17)with subsequent stabilization of TNF receptors. TIMP-3
inhibits the shedding of a number of cell surface molecules. Ahonen
et al. [114] conﬁrmed that TIMP-3 stabilizes three distinct death
receptors (TNF receptor 1, FAS, and TNF-related apoptosis inducing
ligand receptor 1 (TRAIL-R1)) in melanoma cells in culture and in vivo.
TIMP-3 binds to theECMafter secretion [11]. However, recent studiesby
Troeberg et al. [34] indicate that TIMP-3 secreted from cultured
chondrosarcoma cells and chondrocytes does not accumulate in the
extracellular space or medium as it is endocytosed by a LDL receptor
related protein (LRP). The sequestration of TIMP-3 by binding to the
ECM or through endocytosis may help to protect cells from apoptosis
while still allowing it to control pericellular proteolysis through its
potent inhibition of MMPs, ADAMs and ADAMTSs.
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Cartilage, an avascular tissue, contains an anti-angiogenic activity
that is closely associated with anti-proteolytic activity, and the latter
activity was identiﬁed as a collagenase inhibitor [115]. Moses et al.
subsequently isolated the anti-angiogenic activity from bovine
cartilage and found that its N-terminal sequence is similar to that of
human TIMP-1 [116]. It is now well established that all four TIMPs
have anti-angiogenic activity (see [117]). Because a number of MMPs,
particularly gelatinases and MT1-MMP, are involved in endothelial
cell migration and capillary formation, the inhibition of MMPs by
TIMPs can prevent angiogenesis [117]. However, TIMP-2 and TIMP-3
also exhibit anti-angiogenic activity that is independent of their MMP
inhibitory activities.
As discussed above, the anti-angiogenic activity of TIMP-2 is
mediated through its interaction with α3β1 integrin. Feldman et al.
[118] found that the over-expression of TIMP-2 in murine colon
cancer cells inhibited tumor growth and angiogenesis in vivo by up-
regulating MAP kinase phosphatase 1 which dephosphorylates p38
MAPK, a molecule involved in endothelial cell proliferation and
migration. In addition, TIMP-2 enhances the expression of RECK (the
reversion-inducing-cysteine-rich protein with Kazal motif), a mem-
brane-anchored protein with inhibitory activity for MMP-2, -9 and
-14 and ADAM10 [119,120]. Enhanced RECK expression is associated
with the inhibition of endothelial cell migration [121]. The interaction
of TIMP-2 with α3β1 integrin reduces Src tyrosine kinase levels which
alters the pattern of paxillin phosphorylation. This leads to a signaling
switch from Rac 1 to Rap 1, resulting in enhanced RECK expression
and loss of a migratory phenotype [122]. The anti-angiogenic activity
of TIMP-2 has been localized to a region of sequence in the C-terminal
domain [123], whichmay be the site of interaction withα3β1 integrin.
TIMP-3 is also a potent inhibitor of angiogenesis. It binds directly
to VEGF receptor 2 and blocks the action of VEGF on endothelial cells
[124]. TIMP-3 also binds to angiotensin II type 2 receptor, and the
over-expression of both TIMP-3 and angiotensin II type 2 receptor
additively inhibits angiogenesis [125].
TIMP-2 and TIMP-3 also play an important role in the stabilization of
capillary networks during angiogenesis. This process is important as
newly formed capillary networks are predisposed to undergo regres-
sion, and their stabilization requires pericyte recruitment. Saunders et
al. [126] have shown that endothelial cell–pericyte interactions
stimulate the expression of TIMP-3 in pericytes. The TIMP-3 from this
source together with TIMP-2 expressed in endothelial cells participates
in vascular stabilization by inhibiting a number of MMPs and ADAMs
[126] and probably by interacting with VEGFR-2 [124]. These actions of
TIMPs inhibit endothelial cell tube formation and tube regression,which
leads to the cessation of endothelial cell activation and the development
of their quiescence [126]. The recruitment of pericytes and their
interactionwithendothelial cells also stimulate the assembly of vascular
basement membrane matrix assembly which is a crucial step in vessel
maturation [127].5.5. Synaptic plasticity
TIMP-1 was found as a candidate plasticity-related gene whose
expression is greatly increased in the hippocampus on stimulation
with a glutamate analogue, kainate [128]. The hippocampus partici-
pates in synaptic plasticity such as long-term potentiation, seizures,
kindling, learning and memory. TIMP-1-null mice, subjected to a
learning andmemory test in an olfactory maze, exhibited a signiﬁcant
impairment in forming and remembering order-reward associations
[129,130]. This effect is not due to a direct action of TIMP-1 on
memory but is probably mediated by an effect on neuronal
development arising from abnormal ECM turnover during develop-
ment of the central nervous system.Another interesting observation is that TIMP-2-null mice do not
exhibit prepulse inhibition of the startle reﬂex and fear-potentiated
startle [131]. The ability to learn potential dangers and to recall such
stimuli requires long-term changes in synaptic transmission and
structure. This type of synaptic plasticity is thought to be accompanied
by changes in neuronal ECM structure, and TIMP-2 probably affects
neuronal ECMturnover as it is highly expressed in theamygdala, aneural
structure implicated in synaptic plasticity associated with fear condi-
tioning. Neurite outgrowth is greatly reduced in newborn TIMP-2−/−
mice, resulting in defects in neuronal development [105].
TIMP-2-null mice also exhibit symptoms of motor dysfunction,
e.g., decreased time on a motorized rotating rod, reduced hind limb
extension, and splayed and lengthy gait compared with wild-type
mice [132]. These effects are more prominent during postnatal
development and juvenile TIMP-2−/− mice have increased nerve
branching and acetylcholine receptor expression [132]. Adult end-
plates are enlarged and more complex in TIMP-2−/−mice than in the
wild-type, whereas cerebella Purkinje cells have decreased neurite
outgrowth, suggesting that the TIMP-2−/−motor phenotype is due to
both peripheral and central nerve defects resulting from abnormal
ECM turnover [132].
6. Physiological and pathological functions proposed from studies
with TIMP deﬁciency mice
Studies with mice deﬁcient in speciﬁc TIMP genes provide insights
into the physiological and pathological functions of individual TIMPs
in vivo and indicate how ablation of these genes affects ECM
remodeling in the whole animal. Table 3 summarizes the phenotypes
observed in single TIMP deﬁcient mice, and we discuss them here
brieﬂy.
6.1. TIMP-1−/− mice
Nothnick and colleagues found that TIMP-1-null mice exhibit a
number of alterations in processes associated with reproduction and
steroidogenesis (see Table 3), suggesting that TIMP-1 has a multifac-
eted role in regulating the murine reproductive cycle involving the
uterus, ovary and testis. TIMP-1 is also an important regulator of heart
tissue remodeling. TIMP-1−/−mice display changes in left ventricular
structure and cardiac function [133]; they also display exacerbated
left ventricular remodeling after myocardial infarction [134,135].
Partial hepatectomy in mice increases TIMP-3 mRNA within 6 h
and TIMP-1 and TIMP-4 mRNAs by 48 h. A number of MMPs are also
upregulated in regenerating livers in these time periods. Transgenic
mice that underexpress TIMP-1 display accelerated hepatocyte cell
cycle progression, and in TIMP-1−/− mice HGF activity release from
the ECM is increased in regenerating liver, leading to an increase in
the phosphorylation of cMet receptor and activation of p38 MAPK
[136]. TIMP-1 over-expressing mice delayed cell cycle progression,
suggesting that TIMP-1 negatively regulates HGF activity during liver
regeneration by regulating the activities of MMPs that activate and
release pro-HGF from the ECM [136].
TIMP-1-null mice have increased resistance to corneal and
pulmonary infection by Pseudomonas aeruginosa [137]. This was
reversed by a MMP inhibitor, indicating that it results from a loss of
MMP inhibitory activity. MMP-9, MMP-7 and MMP-3 are considered
to be important for resistance to infections, but the mechanism of
their inﬂuence is not known. Possibilities include the alteration of
innate immunity by MMP-7-catalyzed conversion of pro-defensin to
active defensin [138] or the cleavage of syndecan-1 and mobilization
of chemokines [139].
Another interesting phenotype of TIMP-1−/−mice is a decrease in
adipose tissue weight when on a high fat diet [140]. This appears to
contrast with the increased food intake presented by TIMP-1−/−
female mice despite their hyperleptinemia [141]. Since leptin
Table 3
Mouse phenotypes resulting from deletion of individual TIMP genes.
Genotype Phenotype Ref.
TIMP-1−/− ▪ Decreased serum testosterone levels [179]
▪ Reduced serum progesterone levels during copus lutereum development [180]
▪ Enhanced estrogen-induced uterine edema [181]
▪ Decrease in the length of estrus period and altered uterine morphology [182]
▪ Accelerated endometrial gland formation during early postnatal uterine development [183]
▪ Increased resistance to infection by Pseudomonas aeruginosa due to increased inﬂammatory and
complement-dependent immune response
[137]
▪ Resistant to kainite-induced excitotoxicity in hippocampus and showed the typical mossy ﬁber sprouting [129]
▪ Impaired learning and memory [129,130]
▪ Reduced luminal obliteration and increased re-epithelialization after tracked transplantation
(reduced airway ﬁbrosis)
[184]
▪ Enhanced acute lung injury after bleomycin exposure (increased MMP-9 activity in alveoli) [185]
▪ Increased HGF activity in regenerating livers [136]
▪ Decreased adipose tissue weight in high fat diet induced obesity [140]
▪ Hyperphagia and obesity in female mice (standard chow-diet) [141]
▪ Altered left ventricular (LV) geometry and cardiac function [133]
▪ Exacerbated LV remodeling after myocardial infarction [134,135]
TIMP-2−/− ▪ Impairment of pro-MMP-2 activation by MMP-14 [186,187]
▪ Motor dysfunction (increased nerve branching and acetylcholine receptor expression; decreased cerebellar
neurite outgrowth)
[132]
▪ Delayed neuronal differentiation (persistence of nestin-positive progenitors in the neocortical ventricular zone) [104]
▪ Defect in prepulse inhibition and fear-potentiated startle [131]
▪ Weakened muscle and reduced fast-twitch muscle (extensor digitorum longus) mass [143]
▪ Altered myotube formation [142]
TIMP-3−/− ▪ Spontaneous air space enlargement and impaired lung function in aged mice [144]
▪ Accelerated apoptosis during mammary gland involution [145]
▪ Impaired bronchiole branching morphogenesis [148]
▪ Chronic hepatic inﬂammation and failure of liver regeneration [152]
▪ Spontaneous dilated cardiomyopathy (left ventricular (LV) dilation, cardiomyocyte hypertrophy and
contractile dysfunction with elevated MMP-9 and activation of the TNFα system)
[146]
▪ LV dilation and dilated cardiomyopathy following aortic banding [150]
▪ Accelerated cardiac dilation and matrix disruption following a myocardial infarction [188]
▪ Resistance to a brief (30 min) middle cerebral artery occlusion and partial resistance against oxygen-glucose
deprivation-induced neuronal cell death and increased Fas L shedding
[189]
▪ Abnormal vascularization with dilated capillaries throughout the choroid and increased angiogenesis due to
an unbalanced VEGF-mediated angiogenesis
[147]
▪ Enhanced metastatic dissemination of cancer cells to multiple organs [157]
▪ Enhanced tumor growth and angiogenesis [156]
▪ Increased susceptibility to LPS-induced mortality [153]
▪ Increased inﬂammatory response to intra-articular antigen-induced arthritis [190]
▪ Increased pulmonary compliance following LPS challenge, but not mechanical ventilation and hyperoxia [191]
▪ Spontaneous development of arthritis in aged mice [149]
TIMP-3+/− ▪ Accelerated type 2 diabetes when combined with insulin receptor heterozygosity [154]
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TIMP-1 contributes to the regulation of feeding and energy balance. It
is also notable that TIMP-1−/− mice have impaired learning and
memory as discussed above.
6.2. TIMP-2−/− mice
TIMP-2-null mice display a number of phenotypes associated with
defects in the central nervous system and myogenesis (see Table 3).
As discussed earlier, TIMP-2−/−mice exhibit a deﬁciency in prepulse
inhibitor of the startle reﬂex (a measure of pre-attentional sensori-
motor gating) and in the acquisition of fear-potentiated startle, a
model of synaptic plasticity in the amygdala [131]. They also have
motor defects, decreased cerebellar neurite outgrowth [132], and
delayed neuronal differentiation [104]. These effects are probably due
to an abnormal turnover of neuronal ECM and indicate that TIMP-2 is
an important promoter of neuronal differentiation.Altered myotube formation by TIMP-2−/− myoblasts [142] and
weakened muscle and reduced fast-twitch muscle mass in TIMP-2−/−
mice have been reported [143]. In both cases the level of β1 integrin is
altered; also, its level is reduced in the fast-twitchmuscle of TIMP-2−/−
mice [143], suggesting that ECM-cytoskeletal interactions required for
muscle contraction are destabilized.
6.3. TIMP-3−/− mice
Khokha et al. generated TIMP-3−/−mice and initially reported two
prominent phenotypes: air space enlargement in lungs [144] and
enhanced apoptosis during mammary gland involution [145]. Both
result from enhanced matrix degradation resulting from a lack of
metalloproteinase inhibition, suggesting that TIMP-3 is an important
regulator of matrix-degrading metalloproteinases.
Unbalanced matrix degradation is also seen in other tissues causing
dilated cardiomyopathy [146], abnormal vascularization with dilated
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[148], and spontaneous development of arthritis in aged mice [149].
When challenged with disease models linked to inﬂammation and
ECM remodeling, the inﬂammatory process and tissue destruction
were accelerated due to a large increase in metalloproteinase activities.
TIMP-3−/− mice challenged with mechanical stress to the heart,
inducedbyconstriction (aortic banding) of the aorta, exhibit accelerated
development of dilated caridomyopathy due to increased pro-tumor
necrosis factor-α (TNFα) processing by ADAM17 (TACE) and enhanced
MMP-mediated ECM degradation [150]. These mice also manifest
excessive myocardial ﬁbrosis accompanied by a parallel increase of
TGFβ1 andTNFα signaling, ampliﬁed by their cross-talk, suggesting that
TIMP-3 is a common innate regulator of TGFβ1 and TNFα in tissue
responses to injury [151]. Liver regeneration after partial hepatectomy
in TIMP-3−/− mice was impaired because of abnormal inﬂammation
that increases the release of TNFα, suggesting that ADAM17 is oneof the
major targets of TIMP-3 in this system [152]. The loss of TIMP-3 impacts
innate immunity by dysregulating the cleavage of TNFα and its
receptors [153]; in response to lipopolysaccharide (LPS), TIMP-3−/−
macrophages released more TNFα and TIMP-3−/− mice became more
susceptible to endotoxin shock as the result of greatly increased serum
levels of TNFα.
Insulin receptor-haploinsufﬁcient (Insr+/−) mice that are diabetic
have a defect in TIMP-3 expression and increased levels of ADAM17
activity, resulting in elevated levels of soluble TNFα. Doubly heterozy-
gous Insr+/−/Timp3+/−mice exhibitedmore pronounced symptoms of
diabetes and vascular inﬂammation resulting from increased TNFα
[154]. Blocking ADAM17 activity with a synthetic metalloproteinase
inhibitor or anti-TNFα antibody treatment led to marked reduction of
hyperglycemia and vascular inﬂammation in Insr+/− diabetic mice
[154]. TIMP-3−/−mice fedahigh fat diet developedglucose-intolerance
and insulin-resistance [155]. These studies suggest that TIMP-3 is
an important protectant against type 2 diabetes by regulating TNFα
shedding.
TIMP-3−/− tumor cells do not show changes in tumorigenesis
(tumor growth and angiogenesis) when compared with TIMP-3+/+
tumor cells, but B16F10melanoma cells that had been subcutaneously
injected into TIMP-3−/− mice grew faster and displayed increased
angiogenesis relative to those injected into wild-type mice [156]. In
response to FGF-2, TIMP-3−/− endothelial cells invaded more
effectively and formed functional blood vessels in vitro [156].
Enhanced dissemination of lymphoma and melanoma cells to
multiple organs was reported in TIMP-3−/− mice [157]. These
observations indicate that TIMP-3 expressed within the tumor
microenvironment has suppressive effects on tumorigenesis and
metastatic colonization.
Together, these studies show that TIMP-3 is a key endogenous
regulator of metalloproteinases involved in ECM turnover/tissue
destruction, inﬂammation, innate immunity and cancer progression.
7. Sorsby fundus dystrophy
Mutations in the region of the human TIMP-3 gene that encodes
the C-terminal domain are the cause of Sorsby fundus dystrophy
(SFD), an autosomal dominant retinal disorder that results in macular
degeneration and blindness in the 3rd and 4th decades of life [158].
The clinical symptoms are similar to those of age-related macular
degeneration (AMD), except the earlier age of SFD onset. The
mutations that cause SFD in different families variously result in the
substitution of different residues in the C-terminal domain by a
cysteine [159], a nonsensemutation [160], a splicemutation [161] or a
His158Argmutation [162]. Apart from the His158Argmutation, which
is associated with a later onset of disease (5th to 7th decades) than
other SFD mutations, all SFD mutations result in an odd number of
cysteines in the TIMP-3 C-terminal domain. The mutated proteins
appear to dimerize or multimerize through intermolecular disulﬁdebridges [159] or form aberrant TIMP-3–ECM complexes [163], which
may explain the increased deposition of SFD TIMP-3 mutants in Bruch
membrane. The MMP inhibitory activities of SFD mutants are variable
depending on mutants and enzymes tested but do not consistently
show losses of inhibitory activity [163–166], and a loss of function
does not correlate well with the autosomal dominant nature of SFD.
Cells expressing SFD TIMP-3 mutants are more adherent to the ECM
than those expressing wild-type TIMP-3 [163] and SFD TIMP-3
mutants induce apoptosis of retinal pigment epithelial (RPE) cells
more readily than the wild-type protein [167]. Another proposal is
that TIMP-3 SFD mutants may have greater stability than wild-type
TIMP-3 and accumulate in the ECM, affecting its turnover and
producing thickening of the Bruch membrane [168]. This would
become a barrier to the diffusion of nutrients leading to atrophy of the
RPE and photoreceptor death. A possible effect of the SFDmutation on
the half-life of TIMP-3 in the matrix could be signiﬁcant and may
correlate with the ﬁnding that patients with AMD have more TIMP-3
protein in their Bruch membranes than age-matched controls [169].
Studies with a mouse model of SFD generated by introducing the
SFD Ser156Cys mutation in the murine Timp3 gene support the
proposal that site-speciﬁc excess rather than absence or deﬁciency of
functional TIMP-3may be the primary consequence of the Timp3 gene
mutation [170]. Qi et al. [166] recently reported that over-expression
of the Ser156Cys mutant in VEGFR-2-transfected endothelial cells
enhanced VEGF-induced cell proliferation, migration and angiogen-
esis as a consequence of a post-transcriptionally regulated increase in
VEGFR-2 on the cell surface, although the Ser156Cys mutation in
TIMP-3 did not alter the anti-angiogenic activity of TIMP-3 [165].
Malattia leventinese or Doyne honeycomb retinal dystrophy is an
autosomal dominant disorder that also causes early onset macular
degeneration and is linked in an interestingmanner with TIMP-3. This
disease is caused by a mutation in the gene for ﬁbulin 3, an ECM
protein also known as EGF-containing ﬁbulin-like extracellular matrix
protein 1 (EFEMP1) [171], that results in the substitution of Trp for
Arg345 in one of the EGF-like domains. EFEMP1 has been identiﬁed as
a binding partner of TIMP-3 [172] and this interaction was shown by
yeast two-hybrid studies to be mediated by the C-terminal region of
EFEMP1 (residues 256–493) and the C-domain of TIMP-3, both of
which include the mutation sites in their respective diseases. Later
studies have shown that the mutant form of EFEMP1 is not effectively
secreted. When over-expressed in a RPE cell line, it was found to
accumulate in the endoplasmic reticulum, activate the unfolded
protein response and stimulate the production of VEGF [173].
8. Conclusions and future prospects
Because of the relationship of TIMPs with multiple human diseases
and their roles in ECM homeostasis, research on their structures,
functions, and biological and pathological roles continues to ﬂourish, as
reﬂected in the continued growth of the scientiﬁc literature in this area
(702 papers featuring TIMPs in 2008). TIMPs were originally character-
ized as MMP inhibitors, but we now know that their inhibitory spectra
are much broader and include a number of ADAMs and ADAMTSs. This
diverse array of metalloproteinases may, in part, reﬂect similar active
site topologies in these enzymesandalso the extended surfaces in TIMPs
that interact with their targets. These features of TIMPs provide an
opportunity to employ mutational methods to alter their inhibitory
speciﬁcities. The recent success in solving the structure of the complex
of N-TIMP-3 with the catalytic domain of ADAM17 has indicated that
mechanism of inhibition of ADAMs by TIMPs is similar to that forMMPs
[41]. Nevertheless, we have also learned that the non-catalytic domains
of ADAMs and ADAMTSs affect their interactions with TIMP-3. For
example, the inhibition of the complete extracellular region of ADAM17
by TIMP-3 is 10-fold weaker than the inhibition of the truncated
catalytic domain [49], whereas the presence of the C-terminal domains
of ADAMTS-4 and -5 enhances their binding to TIMP-3 [174].
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of ADAM17, suggesting the presence of at least two interactive binding
sites for N-TIMP-3 [50]. Some mutations that largely inactivate TIMP-3
as a MMP inhibitor have little effect on ADAM17 inhibition [50]. Other
TIMPs have varying patterns of inhibition for certain ADAMs as listed in
Table 1. Therefore, elucidation of the characteristics, including the
structural basis, of the molecular interactions of TIMPs with various
forms of ADAMs and ADAMTSs will produce information that may be
useful for engineering selective inhibitors of disintegrin-metalloprotei-
nases. Only limited information is available about the functional
properties of non-mammalian TIMPs particularly those from inverte-
brates. It will be interesting to see how the properties of these TIMPs
relate to evolutionary changes in the ECM and the speciﬁcities of the
metalloproteinases produced by different groups of animals.
Signiﬁcant progress has been made towards understanding the
metalloproteinase inhibition-independent mechanisms of action of
TIMPs that control cell growth, apoptosis, differentiation and anti-
angiogenesis, through identiﬁcation of their receptors, particularly
CD63 for TIMP-1, α3β1 integrin for TIMP-2, and VEGF receptor 2 and
angiotensin II receptor for TIMP-3. Recent studies demonstrating the
endocytosis of TIMP-2 [175] and TIMP-3 [34] through the LRP-
mediated pathway and the age-dependent extracellular accumulation
of TIMP-3 in the kidney, lung and eye [176] have added further
complexity to the biology and pathology of TIMPs. Genetic approaches
have been fruitful in elucidating the physiological and pathological
roles of TIMPs in vivo. Some studies clearly demonstrate that TIMPs
function as regulators of ECM turnover by inhibiting metalloprotei-
nase activities, but in other cases it is unclear whether speciﬁc TIMPs
alter ECM catabolism or exert direct effects on cells. The phenotypes of
TIMP-3-null mice indicate that this inhibitor largely functions as a
metalloproteinase inhibitor in vivo. On the other hand, the molecular
bases for some features of the phenotypes of TIMP-1-null and TIMP-2-
null mice remain obscure. For example, memory and learning deﬁcits
in TIMP-1-null and TIMP-2-null mice are postulated to arise from
abnormal ECM turnover during neuronal development, but the exact
molecular events underlying these interesting phenomena are yet to
be elucidated. The engineering of TIMP variants that interact with the
previously discussed receptors but lack metalloproteinase inhibitory
activity, as well as TIMP variants with selective inhibitory activity
towards speciﬁc metalloproteinases will be useful tools for further
functional studies. TIMP variants that inhibit restricted arrays of
MMPs and disintegrin-metalloproteinases may also be useful for
developing treatments for human diseases related to unregulated
metalloproteinase activity. Further structural and functional studies of
TIMPs, particularly on their interactions with other binding partners
including non-MMPmetzincins, would signiﬁcantly advance the ﬁeld
toward these goals.
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